News

Medison and Ipsen announced that Health Canada has approved Bylvay (odevixibat) for the treatment of cholestatic pruritus in patients aged 12 months and older with Alagille Syndrome…
Read More...

Servier, an international pharmaceutical group, has announced the acquisition of KER-0193, a promising potential treatment for Fragile X syndrome (FXS) from UK-based biotech Kaerus…
Read More...

Eli Lilly and Company announced positive topline results from the Phase 3 BRUIN CLL-313 clinical trial evaluating Jaypirca (pirtobrutinib) in treatment-naïve patients with chronic…
Read More...

Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib, in combination with KEYTRUDA…
Read More...

Argo Biopharmaceutical Co., Ltd., a clinical-stage biotech focused on next-generation siRNA therapies, has announced a new strategic collaboration with Novartis to develop multiple…
Read More...

AbbVie announced that Health Canada has approved ELAHERE® (mirvetuximab soravtansine for injection) under the Priority Review process. ELAHERE is an antibody-drug conjugate (ADC)…
Read More...

Avadel Pharmaceuticals plc, a biopharmaceutical company dedicated to advancing treatments for sleep disorders, has entered into an exclusive global license agreement with XWPharma Ltd.…
Read More...

The U.S. Food and Drug Administration introduced the Rare Disease Evidence Principles (RDEP) to provide greater speed and predictability in the review of therapies intended to treat…
Read More...

Gilead Sciences, Inc. announced a partnership with the U.S. State Department and the United States President’s Emergency Plan for AIDS Relief (PEPFAR) to deliver lenacapavir—Gilead's…
Read More...

Illumina Inc. has officially launched Illumina Protein Prep, a new assay designed to enhance next-generation sequencing (NGS)-based proteomics discovery at scale. Previously available…
Read More...

Amgen has announced plans to invest more than $600 million in a cutting-edge center for science and innovation at its global headquarters in Thousand Oaks, California. The new facility…
Read More...

Quotient Sciences, a global leader in drug development and manufacturing acceleration, has joined forces with UK technology innovation centre CPI to form a joint venture (JV) focused on…
Read More...

Thermo Fisher Scientific Inc. announced the completion of its acquisition of Sanofi’s sterile fill-finish and packaging facility in Ridgefield, New Jersey, expanding its strategic…
Read More...

OMass Therapeutics, a biotech company specializing in medicines targeting complex protein ecosystems, has entered into an exclusive collaboration and license agreement with Genentech, a…
Read More...

Shanghai Henlius Biotech, Inc. and Organon have announced that the U.S. Food and Drug Administration (FDA) has approved BILDYOS (denosumab-nxxp) and BILPREVDA (denosumab-nxxp),…
Read More...

Boehringer Ingelheim announced that its drug HERNEXEOS (zongertinib tablets) has received approval from China’s National Medical Products Administration (NMPA) as a monotherapy…
Read More...

Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for LEQEMBI IQLIK (lecanemab-irmb)…
Read More...

Santhera Pharmaceuticals has entered into an exclusive agreement with Ikris Pharma Network to distribute AGAMREE (vamorolone) in India. The drug is approved for treating Duchenne…
Read More...

The U.S. Food and Drug Administration (FDA) has approved Wayrilz (rilzabrutinib), an oral Bruton’s tyrosine kinase (BTK) inhibitor, for adults with persistent or chronic immune…
Read More...

Novartis has announced encouraging results from its Phase IV V-DIFFERENCE study, which evaluated Leqvio (inclisiran) in patients with high cholesterol who had not met…
Read More...